⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELDN News
Eledon Pharmaceuticals, Inc. Common Stock
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
globenewswire.com
ELDN
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
globenewswire.com
ELDN
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
globenewswire.com
NCEL
ELDN
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
globenewswire.com
ELDN
Form 8-K
sec.gov
ELDN
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
ELDN
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
globenewswire.com
NCEL
ELDN
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
globenewswire.com
NCEL
ELDN
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
prnewswire.com
ELDN
SANA
VCEL
LCTX
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
globenewswire.com
ELDN